SAN DIEGO, Jan. 29 /PRNewswire/ -- ChemDiv, Inc., a leading chemistry-driven global contract research organization, has announced today that it has entered into a discovery collaboration with Achaogen, Inc., South San Francisco, CA. Applying its expertise in medicinal and synthetic chemistry, ChemDiv will support Achaogen in identifying and developing novel antibacterial compounds. Financial terms of the collaboration were not disclosed.
"We look forward to collaborating with Achaogen on this exciting project where ChemDiv's strong medicinal chemistry expertise and integrated drug discovery capabilities will provide our partner with the tools for successful research operations and help them achieve rapid progress in this area," said Alex Khvat, Sr. Director of Chemistry at ChemDiv, Inc.
"We are pleased to be working with ChemDiv on this important medicinal chemistry effort to optimize SOS pathway inhibitors discovered by Achaogen," said Dr. Heinz Moser, Achaogen's Senior Vice President for Chemistry. "These inhibitors could prove to be powerful new tools in the battle against antimicrobial resistance."
About ChemDiv, Inc.:
ChemDiv, Inc. (Chemical Diversity) is a global chemistry-driven contract research organization delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. http://www.chemdiv.com
About Achaogen, Inc.:
Achaogen (a-KAY-oh-jen) is addressing the widespread emergence of
bacterial resistance through the discovery and development of small
molecule anti-infectives. Achaogen focuses on both known classes of
antibiotics, as well as wholly novel classes of new drugs that will act
through validated but as yet unexploited bacterial targets. For more
information about Achaogen please contact John Hollway, Vice President,
|SOURCE ChemDiv, Inc.|
Copyright©2008 PR Newswire.
All rights reserved